Vascular parkinsonism

Therapy

Volumn 5, Issue 2, 2008, Pages 237-255

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Differential diagnosis; Encephalopathy; Multi infarct state; Parkinson's disease; Subcortical arteriosclerotic; Treatment options; Vascular parkinsonian syndrome

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; LEVODOPA;

BRADYKINESIA; BRAIN DEPTH STIMULATION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORPUS STRIATUM; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; EXERCISE; FALLING; FUNCTIONAL ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAIT DISORDER; GLOBUS PALLIDUS; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; INCIDENCE; LEWY BODY; LIFESTYLE MODIFICATION; MUSCLE RIGIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIDOTOMY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING CESSATION; SUBSTANTIA NIGRA; VASCULAR PARKINSONISM; WHITE MATTER;

EID: 41949110621     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.2.237     Document Type: Review

References (173)

1. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33-39 (1999).
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184 (1992).
3. Jellinger KA, Mizuno Y: Parkinson disease. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Dickson DW (Ed.). ISN Neuropath Press, Basel, Switzerland 159-185 (2003).
4. Kosaka K, Yoshimura M, Ikeda K, Budka H: Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin. Neuropathol. 3, 185-192 (1984).
5. McKeith IG, Dickson DW, Lowe J et al.: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872 (2005).
6. Chang CM, Yu YL, Ng HK, Leung SY, Fong KY. Vascular pseudoparkinsonism. Acta Neurol. Scand. 86, 588-592 (1992).
7. Critchley M: Arteriosclerotic pseudoparkinsonism. In: Research Progress in Parkinson's Disease. Rose FC, Capildeo R (Eds). Pitman, London, UK (1981).
8. Critchley M: Arteriosclerotic parkinsonism. Brain 52, 23-83 (1929).
9. Fitzgerald PM, Jankovic J: Lower body parkinsonism: evidence for vascular etiology. Mov. Disord. 4, 249-260 (1989).
10. Sibon I, Tison F: Vascular parkinsonism. Curr. Opin. Neurol. 17, 49-54 (2004).
11. Marie P: Des foyers lacunaires de désintégration et de différents autres états cavitaires do cerveau. Rev. Med. 21, 281-298 (1901).
12. Lhermitte J, Cornil L: Etude clinique de la maladie de Parkinson et des syndromes parkinsoniens do vieillard. Rev. Neurol. (Paris) 37, 625-629 (1921).
13. Souques MA: Rapport sur les. syndromes parkinsoniens. Chapitre III. Causes des syndromes parkinsoniens. Rev. Neurol. (Paris) 37, 548-553 (1921).
14. Vogt C, Vogt O: Zur Lehre der Erkrankungen des striären Systems. J. Psychol. Neurol. 25, 627-846 (1920).
15. Parkes JD, Marsden CD, Rees JE et al.: Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. Q. J. Med. 43, 49-61 (1974).
16. Schwab RS, England AC: Parkinson syndromes due to various specific causes. In: Handboak of Clinicai Neurology. Volume 6. Vinken PJ, Bruyn GW (Eds.) North-Holland Publishing Company, Amsterdam, The Netherlands, 227-247 (1968).
17. Jellinger K: Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45, 1-18 (1987).
18. Jellinger KA: The neuropathologic diagnosis of secondary parkinsonian syndromes. Adv. Neurol. 69, 293-303 (1996).
19. Eadie MJ, Sutherland JM: Arteriosclerosis in parkinsonism. J. Neurol. Neurosurg. Psychiatry 27, 237-240 (1964).
20. Forno LS: Pathology of parkinsonism: nigrostriatal relationships; extranigral lesions. In: Proceedings of a Symposium on Parkinsonism. Worm-Petersen J. Bottcher J (Eds). Merck Sharp & Dohme, Denmark 29-54 (1977).
21. Quinn N: Parkinsonism - recognition and differential diagnosis. BMJ 310, 447-452 (1995).
22. Fenelon G, Houeto JL: [Vascular Parkinson syndromes: a controversial concept]. Rev. Neurol. (Paris) 154, 291-302 (1998).
23. Winikates J, Jankovic J: Clinical correlates of vascular parkinsonism. Arch. Neurol. 56, 98-102 (1999).
24. Fisher CM: Lacunar strokes and infarcts: a review. Neurology 32, 871-876 (1982).
25. Awad IA, Johnson PC, Spetzler RF, Hodak JA: Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke 17, 1090-1097 (1986).
26. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50, 140-148 (1993).
27. Jellinger KA, Attems J: Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol. Scand. 114, 38-46 (2006).
28. Jellinger KA: Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol. (Berl.) 105, 415-419 (2003).
29. Demirkiran M, Bozdemir H, Sarica Y: Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol. Scand. 104, 63-67 (2001).
30. Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ: The L-dopa response in vascular parkinsonism. J. Neurol. Neurosurg. Psychiatry 75, 545-547 (2004).
31. Sibon I, Fenelon G, Quinn NP, Tison F: Vascular parkinsonism. J. Neurol. 251, 513-524 (2004).
32. Thomas M, Jankovic J: Clinical diagnosis of vascular parkinsonism and non-degenerative atypical parkinsonian disorders. In: Current Clinical Neurology: Atypical Parkinsonian Disorders, Litvan, I (Ed.). Humana Press, Totowa, NJ, USA 393-408 (2005).
33. Thanvi B, Lo N, Robinson T: Vascular parkinsonism - an important cause of parkinsonism in older people. Age Ageing 34, 114-119 (2005).
34. Ebersbach G, Poewe W: [Vascular parkinsonian syndrome]. Nervenarzt 77, 139-144, 146-137 (2006).
35. Baldereschi M, di Carlo A, Rocca WA et al.: Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55, 1358-1363 (2000).
36. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA: Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov. Disord. 17, 910-916 (2002).
37. de Reuck J, Sieben G, de Coster W, vander Ecken H: Parkinsonism in patients with cerebral infarcts. Clin. Neurol. Neurosurg. 82, 177-185 (1980).
38. Mancardi GL, Romagnoli P. Tassinari T et al.: Lacunae and cribriform cavities of the brain. Correlations with pseudobulbar palsy and parkinsonism. Eur. Neurol. 28, 11-17 (1988).
39. Schrag A, Ben-Shlomo Y, Quinn NP: Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ 321, 21-22 (2000).
40. Hughes AJ, Daniel SE, Lees AJ: Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57, 1497-1499 (2001).
41. Rajput AH, Rozdilsky B, Rajput A: Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can. J. Neurol. Sci. 18, 275-278 (1991).
42. Jellinger K: Vascular parkinsonism. Comments on Sibon et al.: J. Neurol. 251, 513-524 (2004). J. Neurol. 252, 1549 (2005).
43. Nisbet AP, Daniel SE, Lees AJ: Arteriosclerotic parkinsonism. J. Neurol. Neurosurg. Psychiatry 61, 537 (1996) (Abstract).
44. Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ: Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov. Disord. 19, 630-640 (2004).
45. Jellinger KA: Morphological substrates of parkinsonism, with and without dementia: a retrospective clinico-pathological study. J. Neural. Transm. Suppl. 72, 91-104 (2007).
46. Inzelberg R, Bornstein NM, Reider I, Korczyn AD: Basal ganglia lacunes and parkinsonism. Neuroepidemiology 13, 108-112 (1994).
47. Yamanouchi H, Nagura H: Cerebrovascular parkinsonism - clinicopathologic study Rinsho Shinkeigaku 35, 1457-1458 (1995).
48. Rajput AH, Offord KP, Beard CM, Kurland LT: Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 16, 278-282 (1984).
49. de Rijk MC, Tsourio C, Breteler MM et al.: Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 62, 10-15 (1997).
50. Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM et al.: Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 62, 734-741 (2004).
51. Bhatia KF, Marsden CD: The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 117(Pt 4), 859-876 (1994).
52. Honczarenko K, Budzianowska A: Clinical correlation of vascular parkinsonism. Neurol. Neurochir. Pol. 37(Suppl. 5), 155-164 (2003).
53. Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52, 1214-1220 (1999).
54. van Zagten M, Lodder J, Kessels F: Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov. Disord. 13, 89-95 (1998).
55. Reider-Groswasser I, Bornstein NM, Korczyn AD: Parkinsonism in patients with lucanar infarcts of the basal ganglia. Eur. Neurol. 35, 46-49 (1995).
56. Peralta C, Werner P, Hou B et al.: Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. J. Neural Transm. 111, 1473-1483 (2004).
57. Yamanouchi H, Nagura H: Cerebrovascular parkinsonism - clinicopathologic study. Rinshoo Shinkeigaku 35, 1457-1458 (1995).
58. Weiller C, Ringelstein EB, Reiche W, Thron A, Buell U: The large striatocapsular infarct. A clinical and pathophysiological entity. Arch. Neurol. 47, 1085-1091 (1990).
59. Chung CS, Caplan LR, Yamamoto Y et al.: Striatocapsular haemorrhage. Brain 123(Pt 9), 1850-1862 (2000).
60. Foltynie T, Barker R, Brayne C: Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology 2l, 1-7 (2002).
61. Jellinger K: [The vascular Parkinson syndrome]. Nervenarzt 77, 729-730 (2006).
62. Yomanouchi H, Nagura H: [Cerebrovascular parkinsonism - clinicopathologic study]. Rinsho Shinkeigaku 35, 1457-1458 (1995).
63. Fujimoto K: Vascular parkinsonism. J. Neurol. 253(Suppl. 3), III16-III21 (2006).
64. Rampello L, Alvano A, Battaglia G et al.: Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. J. Neurol. 252, 1045-1049 (2005).
65. da Silva EG, Viana MA, Quagliato EM: Vascular parkinsonism: analysis of seven cases. Arq. Neuropsiquiatr. 64, 568-571 (2006).
66. Kim JS, Lee PH, Lee KS et al.: Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular parkinsonism. Mov. Disord. 21, 1990-1994 (2006).
67. Winikates J, Jankovic J: Vascular progressive supranuclear palsy. J. Neural. Transm. Suppl. 42, 189-201 (1994).
68. Ikeda K, Kotabe T, Kanbashi S, Kinoshita M: Parkinsonism In lacunar infarcts of the basal ganglia. Eur. Neurol. 36, 248-249 (1996).
69. Rektor I, Rektorova I, Kubova D: Vascular parkinsonism - an update. J. Neurol. Sci. 248, 185-191, (2006).
70. Papapetropoulos S, Ellul J, Argyriou AA et al.: The effect of vascular disease on late onset Parkinson's disease. Eur. J. Neurol. 11, 231-235 (2004).
71. Thompson PD, Marsden CD: Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov. Disord. 2, 1-8 (1987).
72. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ: Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 75, 1749-1752 (2004).
73. Gray AJ, Staples V, Murren K. Dhariwal A, Bentham P: Olfactory identification is impaired in clinic-based patients with vascular dementia and senile dementia of Alzheimer type. Int. J. Geriatr Psychiatry 16, 513-517 (2001).
74. Katzenschlager R, Lees AJ: Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr. Opin. Neurol. 17, 417-423 (2004).
75. Dubinsky RM, Jankovic J: Progressive supranuclear palsy and a multi-infarct state. Neurology 37, 570-576 (1987).
76. Zijlmans JC, Pasman JW, Horstink MW et al.: EEG findings in patients with vascular parkinsonism. Acta Neurol. Scand. 98, 243-247 (1998).
77. di Lazzaro V, Oliviero A, Mazzone P et al.: Direct demonstration of long latency cortico-cortical inhibition in normal subjects and in a patient with vascular parkinsonism. Clin. Neurophystol. 113, 1673-1679 (2002).
78. Marchese R, Trompetto C, Buccolieri A, Abbruzzese G: Abnormalities of motor cortical excitability are not correlated with clinical features in atypical parkinsonism. Mov. Disord. 15, 1210-1214 (2000).
79. Zijlmans JC, Thijssen HO, Vogels OJ et al.: MRI in patients with suspected vascular parkinsonism. Neurolgy 45, 2183-2188 (1995).
80. Piccini P, Pavese N, Canapicchi R et al.: White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch. Neurol. 52, 191-194 (1995).
81. Sohn YH, Kim JS: The influence of white matter hyperintensities on the clinical features of Parkinson's disease. Yonsei Med. J. 39, 50-55 (1998).
82. Derejko M, Slawek J, Wieczorek D, Dubaniewicz M, Lass P: [The influence of vascular risk factors and white matter hyperintensities on the degree of motor impairment in Parkinson's disease]. Neurol. Neurochir. Pol. 40, 276-283 (2006).
83. Yamanouchi H, Nagura H: Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 28, 965-969 (1997).
84. Morrow RW, Schweiger GD, Kepes JJ, Koller WC: Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology 40, 897-900 (1990).
85. Laitinen LV, Chudy D, Tengvar M, Hariz MI, Bergenheim, AT: Dilated perivascular spaces in the putamen and pallidum in patients with Parkinson's disease scheduled for pallidotomy: a comparison between MRI findings and clinical symptoms and signs. Mov. Disord. 15, 1139-1144 (2000).
86. Wei GZ: Vascular parkinsonism: verified clinicopathological correlation in a case. Zhonghua Nei Ke Za Zhi 33, 474-476 (1994).
87. Tolosa ES, Santamaria J: Parkinsonism and basal ganglia infarcts. Neurology 34, 1516-1518 (1984).
88. Friedman A, Kang UJ, Tatemichi TK, Burke RE: A case of parkinsonism following striatal lacunar infarction. J. Neurol. Neurosurg. Psychiatry, 49, 1087-1088 (1986).
89. Mayo J, Arias M, Leno C, Berciano J: Vascular parkinsonism and periarteritis nodosa. Neurology 36, 874-875 (1986).
90. Lee MS, Lee SA, Heo JH, Choi IS: A patient with a resting tremor and a lacunar infarction at the border between the thalamus and the internal capsule. Mov. Disord. 8, 244-246 (1993).
91. de la Fuente Fernandez R, Lopez J, Rey del Corral P, de la Iglesia Martinez F: Peduncular hallucinosis and right hemiparkinsonism caused by left mesencephalic infarction. J. Neurol. Neurosurg. Psychiatry 57, 870 (1994).
92. Pullicino P, Lichter D, Benedict R: Micrographia with cognitive dysfunction: "minimal" sequelae of a putaminal infarct. Mov. Disord 9, 371-373 (1994).
93. Kulisevsky J, Avila A, Berthier ML: Bipolar affective disorder and unilateral parkinsonism after a brainstem infarction. Mov. Disord. 10. 799-802 (1995).
94. Mark MH, Sage JI, Walters AS, Duvoisin RC, Miller DC: Binswanger's disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mov. Disord. 10, 450-454 (1995).
95. Boecker H, Weindl A, Leenders K et al.: Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol. Scand. 93, 387-392 (1996).
96. Fenelon G, Houeto JL: Unilateral parkinsonism following a large infarct in the territory of the lenticulostriate arteries. Mov. Disord. 12, 1086-1090 (1997).
97. Tison F, Duche B, Loiseau P: [Vascular hemi-parkinson disease]. Rev. Neurol. (Paris) 149, 565-567 (1993).
98. Fenelon G, Gray F, Wallays C, Poirier I Guillard A: Parkinsonism and dilatation of the perivascular spaces (etat crible) of the striatum: a clinical, magnetic resonance imaging, and pathological study. Mov. Disord. 10, 754-760 (1995).
99. Tohgi H, Takahashi S, Abe T. Utsugisawa K: Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes In the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Eur. Neurol. 46, 1-10 (2001).
100. Akyol A, Akyildiz UO, Tataroglu C: Vascular parkinsonism: a case of lacunar infarction localized to mesencephalic substantia nigra. Parkinsonism Relat. Disord. 12, 459-461 (2006).
101. Reitz C, Trenkwalder C, Kretzschmar K et al.: Relation of cerebral small-vessel disease and brain atrophy to mild parkinsonism in the elderly. Mov. Disord. 21. 1914-1919 (2006).
102. Tsai CF, Wu RM, Huang YW et al.: Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J. Neurol. 254, 501-507 (2007).
103. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G: Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J. Nucl. Med. 42, 408-413 (2001).
104. Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y: 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J. Nucl. Med. 45, 1688-1693 (2004).
105. Zijlmans J, Evans A, Fontes F et al.: [(123)I] FP-CIT SPECT study in vascular parkinsonism and Parkinson's disease. Mov. Disord. 22, 1278-1285 (2007).
106. Scherfler C, Schwarz J, Antonini A et al.: Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord. 22, 1229-1238 (2007).
107. Gerschlager W, Bencsits G, Pirker W et al.: [123I]β-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov. Disord. 17, 518-523 (2002).
108. Marshall V, Grosset D: Role of dopamine transporter imaging in routine clinical practice. Mov. Disord. 18, 1415-1423 (2003).
109. Terashi H, Nagata K, Hirata Y, Hatazawa J, Utsumi H: [Study on dopamine D2 binding capacity in vascular parkinsonism]. Rinsho Shinkeigaku 41, 659-664 (2001).
110. Vaamonde J, Ibanez. R, Garcia AM, Poblete V: Study of the pre and post-synaptic dopamenergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients. Neuralogia 19, 292-300 (2004).
111. Plotkin M, Amthauer H, Quill S et al.: Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases, J. Neural Transm. 112, 1355-1361 (2005).
112. Abe K, Terakawa H, Takanashi M et al.: Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res. Bull. 52, 589-595 (2000).
113. Zijlmans JC, de Koster A, van't Hof MA et al.: Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism. Acta Neurol. Scand. 90, 405-411 (1994).
114. Ihara M, Tomimoto H, Ishizu K et al.: Association of vascular parkinsonism with impaired neuronal integrity in the striatum. J. Neural Transm. 114, 577-584 (2007).
115. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y: Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76, 249-251 (2005).
116. Spiegel J, Mollers MO, Jost WH et al.: FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov. Disord. 20, 552-561 (2005).
117. Jellinger KA: Parkinsonism due to Binswanger's subcortical arteriosclerotic encephalopathy. Mov. Disord. 11, 461-462 (1996).
118. Tan EK, Chan LL, Yu GX et al.: Vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates. Ann, Neurol. 54, 836-840 (2003).
119. Thiam A, Ndiaye MM, Ndiaye IP: [Vascular parkinsonian syndrome in 21 case studies, two of which were anatomic]. Dakar Med. 45, 25-29 (2000).
120. Hsieh CF, Tung CS, Shih PY, Lin WC: Cerebral hemosiderosis as a causative factor of vascular parkinsonism. Acta Neurol. Taiwan 14, 201-207 (2005).
121. Fisher CM: Lacunes: small, deep cerebral infarcts. 1965. Neurology 50, 841 and 811 pages following (1998).
122. Zijlmans JC, Poels PJ, Duysens J et al.: Quantitative gait analysis in patients with vascular parkinsonism. Mov. Disord. 11, 501-508 (1996).
123. Jellinger KA: The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol. (Berl.) 113, 349-388 (2007).
124. Josephs KA, Ishizawa T, Tsuboi Y, Cookson N, Dickson DW: A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy. Arch. Neurol. 59, 1597-1601 (2002).
125. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455 (1973).
126. Fearnley JM, Lees AJ: Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5), 2283-2301 (1991).
127. Forno LS: Reaction of the substantia nigra to massive basal ganglia infarction. Acta Neuropathol. (Berl.) 62, 96-102 (1983).
128. Nakane M, Teraoka A, Asato R, Tamura A: Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke 23, 328-332 (1992).
129. Tamura A, Kirino T, Sano K, Takagi K, Oka H: Atrophy of the ipsilateral substantia nigra following middle-cerebral artery occlusion in the rat. Brain Res. 510. 154-157 (1990).
130. Soriano MA, Justicia, C, Ferrer I, Rodriguez-Farre E, Planas AM: Striatal infarction in the rat causes a transient reduction of tyrosine hydroxylase immunoreactivity in the ipsilateral substantia nigra. Neurobiol. Dis. 4, 376-385 (1997).
131. Ishibashi S, Kuroiwa T, Katsumata N et al.: Extrapyramidal motor symptoms versus striatal infarction volume after focal ischemia in mongolian gerbils. Neuroscience 127, 269-275 (2004).
132. Mengesdorf T, Jensen PH, Mies G, Aufenberg C, Paschen W: Down-regulation of parkin protein in transient focal cerebral ischemia: a link between stroke and degenerative disease? Proc. Natl. Acad. Sci. USA 99, 15042-15047 (2002).
133. Barcia C, Bautista V, Sanchez-Bahillo A et al.: Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J. Neural Tansm. 112, 1237-4248 (2005).
134. Ma KC, Lundberg PO, Lilja A, Olsson Y: Binswanger's disease in the absence of chronic arterial hypertension. A case report with clinical, radiological and immunohistochemical observations on intracerebral blood vessels. Acta Neuropathol. (Berl.) 83, 434-439 (1992).
135. van Gijn J: Leukoaraiosis and vascular dementia. Neurology 51, S3-S8 (1998).
136. Arvanitakis Z, Wilson RS, Bienias JL, Bennett DA: Diabetes and parkinsonian signs in older persons. Alzheimer Dis. Assoc. Disord. 21, 144-149 (2007).
137. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J: Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30, 842-847 (2007).
138. Louis ED, Luchsinger JA: History of vascular disease and mild parkinsonian signs in community-dwelling elderly individuals. Arch. Neurol. 63, 717-722 (2006).
139. Milanov IG. Rashkov R, Baleva M, Georgiev D: Antiphospholipid syndrome and parkinsonism. Clin. Exp. Rheumatol. 16, 623-624 (1998).
140. Huang Z, Jacewicz M, Pfeiffer RF: Anticardiolipin antibody in vascular parkinsonism. Mov. Disord. 17, 992-997 (2002).
141. Zaccolella S, Lamberti P, Iliceto G et al.: Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin. Chem. Lab. Med. 44, 863-866 (2006).
142. Kuhn W, Roebrock R, Blom H et al.: Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol. 40, 225-227 (1998).
143. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R: Elevated plasma homocysteine level in patients treated with levodopa: association with vascular disease. Arch. Neurol. 60, 59-64 (2003).
144. Zoccolella S, Lamberti P, Iliceto G et al.: Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin. Chem. Lab. Med. 43, 1107-1110 (2005).
145. Miller JW, Selhub J, Nadeau MR et al.: Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60, 1125-1129 (2003).
146. Martignoni E, Tassorelli C, Nappi G et al.: Homocysteine and Parkinson's disease: a dangerous liaison? J. Neurol. Sci. 257, 31-37 (2007).
147. Ravaglia G, Forti P, Maioli F et al.: Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr. 82, 636-643 (2005).
148. Hassin-Baer S, Cohen O, Vakil E et al.: Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin. Neuropharmacol. 29, 305-311 (2006).
149. Ben-Shlomo Y: How far are we in understanding the cause of Parkinson's disease? J. Neurol. Neurosurg. Psychiatry 61, 4-16 (1996).
150. Scigliano G, Musicco M, Soliveri P et al.: Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37, 1184-1188 (2006).
151. Korten A, Lodder J, Vreeling F et al.: Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke? Mov. Disord. 16, 119-123 (2001).
152. Nakaso K, Yasui K, Kowa H et al.: Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J. Neurol. Sci. 207, 19-23 (2003).
153. Wichmann T, DeLong MR: Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6, 751-758 (1996).
154. Elble RJ, Cousins R, Leffler K, Hughes L: Gait initiation by patients with lower-half parkinsonism. Brain 119(Pt 5), 1705-1716 (1996).
155. Tohgi H, Utsugisawa K, Yoshimura M et al.: Reduction in the ratio of β-preprotachykinin to preproenkephalin messenger RNA expression in postmortem human putamen during aging and in patients with status lacunaris. Implications for the susceptibility to parkinsonism. Brain Res. 768, 86-90 (1997).
156. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M: Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits α4 and β2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to parkinsonism. Brain Res. 791, 186-190 (1998).
157. Peters S, Eising EG, Przuntek H, Muller T: Vascular parkinsonism: a case report and review of the literature. J. Clin. Neurosci. 8, 268-271 (2001).
158. Dubois B, Pillon B, De Saxce H, Lhermitte F, Agid Y: Disappearance of parkinsonian signs after spontaneous vascular 'thalamotomy'. Arch. Neurol. 43, 815-817 (1986).
159. Krauss JK, Grossman RG, Jankovic J: Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov. Disord. 12, 124-126 (1997).
160. Rivest J, Quinn N, Gibbs J, Marsden CD: Unilateral abolition of extrapyramidal rigidity after ipsilateral cerebellar infarction. Mov. Disord. 5, 328-330 (1990).
161. Scoditti U, Rustichelli P, Calzetti S: Spontaneous hemiballism and disappearance of parksinsonism following contralateral lenticular lacunar infarct. Ital. J. Neurol. Sci. 10, 575-577 (1989).
162. Sellal F, Hirsch E, Lisovoski F et al.: Contralateral disappearance of parkinsonian signs after subthalamic hematoma. Neurology 42, 255-256 (1992).
163. Yamada A, Takeuchi H, Miki H: [Unilateral abolition of parkinsonian rigidity after subthalamic nucleus hemorrhage]. Rinsho Shinkeigaku 32, 887-889 (1992).
164. Braak H, Ghebremedhin, E, Rub U, Bratzke H, del Tredici K: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134 (2004).
165. Leduc V, Montagne B, Destée A: Parkinsonism consecutive to an hemorrhagic lesion of the substantia nigra. Mov. Disord. 12(Suppi. 1), 2 (1997).
166. Ondo WG, Cla n LL, Levy JK: Vascular parkinsonism: clinical correlates predicting motor improvement after lumbar puncture. Mov. Disord. 17, 91-97 (2002).
167. Goto S, Kunitoku N, Soyama N et al.: Posteroventral pallidotomy in a patient with parkinsonism caused by hypoxic encephalopathy. Neurology 49, 707-710 (1997).
168. Krack P, Dowsey PL, Benabid AL et al.: Ineffective suathalamic nucleus stimulation in levodopa-resistant postischemic parkinsonism. Neurology 54, 2182-2184 (2000).
169. de Vecchi AF, Novembrino C, Patrosso MC et al.: Effect of incremental doses of folate on homocysteine and metabolically related vitamin concentrations n nondiabetic patients on peritoneal dialysis. Asaio J. 49, 655-659 (2003).
170. Geng B, Chang L, Du JB, Tang CS: [A new strategy to treat hyperhomocysteinemia]. Beijing Da Xue Aue Bao 37, 215-219 (2005).
171. Paraskevas GF, Kapaki E, Petropoulou O et al.: Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism. J Neurol. Sci. 215, 51-55 (2003).
172. Guerini F, Frisoni GB, Bellwald C et al.: Subcortical vascular lesions predict functional recovery after rehabilitation in patients with L-dopa refractory parkinsonism. J Am. Geriatr. Soc. 52, 252-256 (2004).
173. Atchison PR, Thompson PD, Frackowiak RS, Marsden CD: The syndrome of gait ignition failure: a report of six cases. Mov. Disord. 8, 285-292 (1993).